Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…h individual and combination LLT, including statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors. Admission lipid profile and pre-ACS LLT …
…high-intensity statin and only 2 older patients were prescribed ezetimibe.Conclusion Achievement of secondary prevention targets is low i…
…), 0.3 days for Dapagliflozin (95%CI 0.4–0.2), and 0.3 days for Alendronic Acid (95%CI 0.4–0.2).Dispensing practices more consistently prescrib…
… long-term dual antithrombotic therapy (low-dose rivaroxaban or ticagrelor). This study compared cardiovascular outcomes of patients seen …
…sing a proprotein convertase subtilisin/kexin type 9 inhibitor, ezetimibe, and high-intensity statin after endovascular thrombectomy (EVT…
…n-fatal MIs occurred; 1 fatal MI, 1 fatal intracranial bleed on aspirin, 4 non-cardiac/undocumented deaths. Figures below illustrate an…
…ee patients developed mild injection-site skin rash.Conclusions Inclisiran produced substantial and clinically meaningful reductions in LD…
…ntion populations.2 This analysis assesses the effectiveness of bempedoic acid, a non-statin lipid-lowering therapy, in achieving NICE non-HDL…
… findings highlight the need for combination therapies, such as bempedoic acid, to optimize lipid management and achieve NICE targets in prima…
…ent increased from 5% to 79%. Upfront dual therapy (statin plus ezetimibe) was introduced for selected patients with significantly elevat…
…ls and 89.4% of patients on high intensity statin combined with ezetimibe achieved targets. Patients who decided for non-pharmacological …
…s with hypercholesterolaemia treated with PCSK9i (alirocumab or evolocumab).To assess the acceptance rate of the interventions.Material an…